Parkinson's disease is a brain disorder. It occurs when certain nerve cells (neurons) in a part of the brain called the substantia nigra die or become impaired. When approximately 80 percent of neurons are damaged, the symptoms of Parkinson's disease appear. Parkinson's disease affects 1 in 100 people over the age of 60, with the average age of onset being 60 years. The risk of developing Parkinson's disease increases with age. In the United States, it is estimated that 60,000 new cases of Parkinson's disease are diagnosed each year, with 1.5 million Americans currently living with the disease.
Infrared analyses of neuronal proteins provide information on molecular changes in patients with ALS. This helps to verify their diagnosis.
In many neurodegenerative diseases like Parkinson's, protein aggregates form in the brain and are assumed to contribute to neuronal cell death.
The shells of crustaceans and wood waste such as branches pruned from trees usually end up in landfills. These waste materials are given a new lease of life to become nutritional supplements and medicine, with the help of a novel process developed by researchers from the National University of Singapore (NUS).
New research shows a simple skin test can accurately identify Parkinson's disease, demonstrating for the first time the feasibility of the method. Currently diagnosed by clinical signs and symptoms but only definitively diagnosed at autopsy, Parkinson's disease is commonly misdiagnosed early in the disease course, complicating clinical trials of potential treatments.
Variations in a gene that regulates dopamine levels in the brain may influence the mobility of elderly and frail adults, according to new research from the University of Pittsburgh Graduate School of Public Health.
In first-of-their-kind observations in the human brain, an international team of researchers has revealed two well-known neurochemicals -- dopamine and serotonin -- are at work at sub-second speeds to shape how people perceive the world and take action based on their perception.
The death of neurons, whether in the brain or the eye, can result in a number of human neurodegenerative disorders, from blindness to Parkinson's disease.
The mature brain is infamously bad at repairing itself following damage like that caused by trauma or strokes, or from degenerative diseases like Parkinson's.
Scientists have created an animal model that simulates cerebellar neurodegeneration and motor dysfunction.
A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye.
Hard skulls help protect our brains from physical injuries.In addition to a tough outer shell, brains have internal defenses, including a powerful shield called the blood-brain barrier that defends brain cells from substances in the bloodstream that are toxic and dangerous to nerve cells. If the blood-brain barrier is breached, then health problems arise.
A Rutgers-led team has created a smart drug delivery system that reduces inflammation in damaged nervous tissues and may help treat spinal cord injuries and other neurological disorders.
In a seven-year research effort, an international team of scientists has clarified the cause for certain genetic forms of Parkinson's disease, and has identified potential pharmacological treatments.
Inspired by the need for new and better therapies for neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, Rutgers University researchers are exploring the link between uncontrolled inflammation within the brain and the brain's immune cells, known as microglia.
A new study using induced pluripotent stem cell (iPSC) technology links astrocyte dysfunction to Parkinson's disease (PD) pathology.
TK Adenosine triphosphate, or ATP, is the cellular energy currency that is as valuable to the human body as the dollar is to the US economy. Too high or too low levels of ATP in some cell types have been linked to a variety of diseases.
Scientists have made a breakthrough in understanding how the enteric nervous system forms, which could pave the way for new treatments for neurodegenerative diseases such as Parkinson's.
Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies.
Switching off a molecular "master regulator" may protect the brain from inflammatory damage and neurodegeneration in Parkinson's disease, reports a study published today in Nature Neuroscience.
Whether you are playing Go in a park amid chirping birds, a gentle breeze and kids playing catch nearby or you are playing in a den with a ticking clock on a bookcase and a purring cat on the sofa, if the game situation is identical and clear, your next move likely would be, too, regardless of those different conditions.